Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery

Drug Discovery Today

Volumn 20, Issue 5, 2015, Pages 536-547

  Kesharwani, Prashant ^a   Iyer, Arun K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRIMER; DRUG CARRIER; NANOPARTICLE;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENE THERAPY; GENE TRANSFER; HUMAN; METABOLISM; NANOMEDICINE; STRUCTURE ACTIVITY RELATION; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DENDRIMERS; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; MOLECULAR STRUCTURE; NANOMEDICINE; NANOPARTICLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939968965     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.12.012     Document Type: Review

References (115)

1. J. Ferlay Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int. J. Cancer 2014 10.1002/ijc.29210
2. P. Kesarwani Spectrophotometric estimation of paclitaxel Int. J. Adv. Pharm. Sci. 2 2011 29 32
3. D. Peer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
4. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
5. S.K. Sahoo, and V. Labhasetwar Nanotech approaches to drug delivery and imaging Drug Discov. Today 8 2003 1112 1120
6. S.C. Abeylath Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery Acc. Chem. Res. 44 2011 1009 1017
7. A.K. Iyer Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors Mol. Pharm. 11 2014 2511 2526
8. R. Bazak Passive targeting of nanoparticles to cancer: a comprehensive review of the literature Mol. Clin. Oncol. 2 2014 904 908
9. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
10. A.K. Iyer Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov. Today 11 2006 812 818
11. P. Kesharwani Carbon nanotube exploration in cancer cell lines Drug Discov. Today 17 2012 1023 1030
12. T. Islam, and L. Josephson Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles Cancer Biomark. 5 2009 99 107
13. Y. Teow, and S. Valiyaveettil Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles Nanoscale 2 2010 2607 2613
14. R.K. Tekade Dendrimers in oncology: an expanding horizon Chem. Rev. 109 2009 49 87
15. S.S. Abolmaali A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis Cancer Chemother. Pharmacol. 71 2013 1115 1130
16. A.K. Iyer Role of integrated cancer nanomedicine in overcoming drug resistance Adv. Drug Deliv. Rev. 65 2013 1784 1802
17. L. Mei Pharmaceutical nanotechnology for oral delivery of anticancer drugs Adv. Drug Deliv. Rev. 65 2013 880 890
18. C.A. Schutz Therapeutic nanoparticles in clinics and under clinical evaluation Nanomedicine (Lond.) 8 2013 449 467
19. A. Puri Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic Crit. Rev. Ther. Drug Carr. Syst. 26 2009 523 580
20. N. Shcharbina Nanomaterials in stroke treatment: perspectives Stroke 44 2013 2351 2355
21. P. Dande Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications J. Med. Chem. 49 2006 1624 1634
22. E. Bardi Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer Pathol. Oncol. Res. 13 2007 249 253
23. V. Ferraresi Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a Phase II study Am. J. Clin. Oncol. 23 2000 132 139
24. T. Smit Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice Anticancer Drugs 16 2005 501 506
25. S. Thakur The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers J. Nanopart. Res. 15 2013 1625
26. S. Parveen, and S.K. Sahoo Polymeric nanoparticles for cancer therapy J. Drug Target. 16 2008 108 123
27. E.K. Pauwels, and P. Erba Towards the use of nanoparticles in cancer therapy and imaging Drug News Perspect. 20 2007 213 220
28. Y. Liu Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles Int. J. Cancer 120 2007 2527 2537
29. N.P. Praetorius, and T.K. Mandal Engineered nanoparticles in cancer therapy Recent Pat. Drug Deliv. Formul. 1 2007 37 51
30. I. Brigger Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 2002 631 651
31. B.K. Nanjwade Dendrimers: emerging polymers for drug-delivery systems Eur. J. Pharm. Sci. 38 2009 185 196
32. D.A. Tomalia Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic organic chemistry Aldrichim. Acta 37 2004 39
33. D.A. Tomalia A new class of polymers - starburst-dendritic macromolecules Polym. J. 17 1985 117 132
34. H. Ihre Fast and convenient divergent synthesis of aliphatic ester dendrimers by anhydride coupling J. Am. Chem. Soc. 123 2001 5908 5917
35. H.L. Crampton, and E.E. Simanek Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers Polym. Int. 56 2007 489 496
36. D.A. Tomalia Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging Biochem. Soc. Trans. 35 2007 61 67
37. M. Na Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies Eur. J. Med. Chem. 41 2006 670 674
38. A.K. Patri Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex Adv. Drug Deliv. Rev. 57 2005 2203 2214
39. E.R. Gillies, and J.M. Frechet Dendrimers and dendritic polymers in drug delivery Drug Discov. Today 10 2005 35 43
40. M. Liu, and J.M. Frechet Designing dendrimers for drug delivery Pharm. Sci. Technol. Today 2 1999 393 401
41. P. Kesharwani Dendrimer as nanocarrier for drug delivery Prog. Polym. Sci. 39 2014 268 307
42. P. Kesharwani Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer Biomaterials 35 2014 5539 5548
43. R.M. Kannan Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications J. Intern. Med. 276 2014 579 617
44. P. Kesharwani Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector Nanomedicine (Lond.) 9 2014 2291 2308
45. K. Greish Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting Clin. Pharmacokinet. 42 2003 1089 1105
46. H. Maeda Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Control. Release 74 2001 47 61
47. M.R. Dreher Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98 2006 335 344
48. F. Yuan Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 1995 3752 3756
49. H. Maeda Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
50. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41 2001 189 207
51. W. She Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy Biomaterials 34 2013 2252 2264
52. L.M. Kaminskas Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties Nanomedicine (Lond.) 6 2011 1063 1084
53. G. Orive Micro and nano drug delivery systems in cancer therapy Cancer Ther. 3 2005 131 138
54. R. Duncan, and L. Izzo Dendrimer biocompatibility and toxicity Adv. Drug Deliv. Rev. 57 2005 2215 2237
55. S.T. Lo Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry Mol. Pharm. 10 2013 793 812
56. A. Agarwal Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent Biomaterials 30 2009 3588 3596
57. M.M. Gottesman Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
58. R.K. Jain Barriers to drug delivery in solid tumors Sci. Am. 271 1994 58 65
59. L. Jia Polyamidoamine dendrimers surface-engineered with biomimetic phosphorylcholine as potential drug delivery carriers Colloids Surf. B: Biointerfaces 84 2011 49 54
60. Y. Zhang Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent Bioorg. Med. Chem. 19 2011 2557 2564
61. A. Sharma Surface modified dendrimers: synthesis and characterization for cancer targeted drug delivery Bioorg. Med. Chem. 19 2011 3341 3346
62. W. Yang Targeting cancer cells with biotine-dendrimer conjugates Eur. J. Med. Chem. 44 2009 862 868
63. H. Hui Thermo- and pH-sensitive dendrimer derivatives with a shell of poly(N,N-dimethylaminoethyl methacrylate) and study of their controlled drug release behavior Polymer (Guildf.) 46 2005 9514 9522
64. A. Quintana Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor Pharm. Res. 19 2002 1310 1316
65. D. Bhadra A PEGylated dendritic nanoparticulate carrier of fluorouracil Int. J. Pharm. 257 2003 111 124
66. H. He PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors Biomaterials 32 2011 478 487
67. R.K. Tekade Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics J. Microencapsul. 26 2009 287 296
68. H.C. Gerard Dendrimer-enabled DNA delivery and transformation of Chlamydia pneumoniae Nanomedicine 9 2013 996 1008
69. M.A. Broeren Multivalency in the gas phase: the study of dendritic aggregates by mass spectrometry Angew. Chem. Int. Ed. Engl. 43 2004 3557 3562
70. K. Wada Enhancing effects of galactosylated dendrimer/alpha-cyclodextrin conjugates on gene transfer efficiency Biol. Pharm. Bull. 28 2005 500 505
71. H. Arima Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins Bioconjug. Chem. 12 2001 476 484
72. Q. Yuan Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery Oral Oncol. 46 2010 698 704
73. L. Vincent Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies Int. J. Cancer 105 2003 419 429
74. J.F. Kukowska-Latallo Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector Hum. Gene Ther. 11 2000 1385 1395
75. H.Y. Nam Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery Int. J. Pharm. 363 2008 199 205
76. M.L. Patil Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery Bioconjug. Chem. 19 2008 1396 1403
77. M.L. Patil Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing ACS Nano 5 2011 1877 1887
78. P. Kesharwani Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison Nanomedicine 7 2011 295 304
79. Z. Sideratou Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system Bioorg. Med. Chem. Lett. 20 2010 6513 6517
80. R.S. Dhakad Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone Curr. Drug Deliv. 10 2013 477 491
81. U. Gupta Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells Int. J. Pharm. 393 2010 185 196
82. S.H. Medina Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells Biomaterials 34 2013 4655 4666
83. V. Gajbhiye, and N.K. Jain The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates Biomaterials 32 2011 6213 6225
84. S.K. Patel Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates J. Drug Target. 20 2012 841 849
85. S.I. Pai Prospects of RNA interference therapy for cancer Gene Ther. 13 2006 464 477
86. L. Aagaard, and J.J. Rossi RNAi therapeutics: principles, prospects and challenges Adv. Drug Deliv. Rev. 59 2007 75 86
87. V. Reebye Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo Hepatology 59 2014 216 227
88. K.A. Whitehead Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
89. O. Taratula Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery J. Control. Release 140 2009 284 293
90. O. Taratula Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes Curr. Drug Deliv. 8 2011 59 69
91. C. Dufes Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors Cancer Res. 65 2005 8079 8084
92. V. Russ Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery J. Control. Release 132 2008 131 140
93. H. Liu Fluorinated poly(propylenimine) dendrimers as gene vectors Biomaterials 35 2014 5407 5413
94. http://www.starpharma.com/drug-delivery/dep-docetaxel
95. K. Jain Dendronized nanoconjugates of lysine and folate for treatment of cancer Eur. J. Pharm. Biopharm. 87 2014 500 509
96. T. Niidome Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(l-lysine) J. Biomater. Sci. Polym. Ed. 25 2014 1362 1373
97. K.T. Al-Jamal Cationic poly-l-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo ACS Nano 7 2013 1905 1917
98. L.M. Kaminskas Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy J. Control. Release 183 2014 18 26
99. M. Ohsaki In vitro gene transfection using dendritic poly(l-lysine) Bioconjug. Chem. 13 2002 510 517
100. D. Ma New cyclodextrin derivative containing poly(l-lysine) dendrons for gene and drug co-delivery J. Colloid Interface Sci. 405 2013 305 311
101. D. Ma Photoenhanced gene transfection by a star-shaped polymer consisting of a porphyrin core and poly(l-lysine) dendron arms Macromol. Biosci. 13 2013 1221 1227
102. W. Zheng Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance Acta Biomater. 11 2014 368 380
103. F. Fu Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer ACS Appl. Mater. Interfaces 6 2014 16416 16425
104. A.F. Abdelwahab Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronyl glucosyl-beta-cyclodextrin (G3) as a novel carrier for siRNA J. Drug Target. 22 2014 927 934
105. Z. Gu Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery Drug Dev. Ind. Pharm. 2014 (Epub ahead of print)
106. K. Wang Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release Drug Deliv. 2014 (Epub ahead of print)
107. S. Yalcin Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines Biomed. Pharmacother. 68 2014 737 743
108. D. Pooja Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes Colloids Surf. B: Biointerfaces 121 2014 461 468
109. X. Liu Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system Nanomedicine 10 2014 1627 1636
110. K. Urbiola Efficient targeted gene delivery by a novel PAMAM/DNA dendriplex coated with hyaluronic acid Nanomedicine (Lond.) 2014 1 15
111. X. Li PEGylated PAMAM dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy Biomaterials 35 2014 6576 6584
112. B. Birdhariya Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers Drug Dev. Ind. Pharm. 2014 1 7
113. V. Shah Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug Clin. Cancer Res. 19 2013 6193 6204
114. F. Wang Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation Acta Biomater. 8 2012 4304 4313
115. J. Zhao Cell-penetrable lysine dendrimers for anti-cancer drug delivery: synthesis and preliminary biological evaluation Arch. Pharm. (Weinheim) 347 2014 469 477